Cancer Medicines Forum: September 2025
EventHumanMedicines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
- The original event time is:
- Thursday, September 4, 2025 - 14:00 - 17:00 Amsterdam time (CEST)
Date
- , -
Location
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
Event summary
Setting up in March 2022, the Cancer Medicines Forum (CMF) was created by EMA in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) with the overall goal to optimise cancer treatments.
During the September 2025 meeting, the following topics were discussed:
- Preparation for the November 2025 CMF workshop
Members reviewed plans for the upcoming workshop, which will focus on strengthening collaboration between industry and academia in treatment-optimisation clinical trials: EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation - Collaboration with the European Society of Oncology Pharmacists (ESOP)
ESOP outlined its current activities and acknowledged the CMF’s efforts to address challenges faced by oncology pharmacists, particularly issues related to defining low-intervention clinical trials and clarifying regulatory requirements for Investigational Medicinal Products. ESOP also highlighted drug–drug interactions as an important area for future work, noting that real-world patients often use multiple medications and herbal products that are generally excluded as concomitant therapies in clinical trials. - Update on a bladder cancer treatment-optimisation study
The EORTC presented progress on a study evaluating the optimal treatment duration of an antibody–drug conjugate in previously untreated advanced urothelial cancer. The study is intended as a pilot in which healthcare systems would contribute financially to trial execution, in return for access to the study results and underlying dataset.